Q&A: New Myeloma Bispecific Rivals CAR T in Early Data

CHICAGO — Two early-phase clinical trials released data at the American Society of Clinical Oncology (ASCO) 2025 annual meeting that suggest their premise — an elranatamab-based triplet regimen and a new trispecific regimen — shows good potential in multiple myeloma (MM). “It was interesting to see where these new lines of thought will take us …